| Document |
Document Title |
|
WO/2020/005873A1 |
The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. Formula (I). In particula...
|
|
WO/2019/243535A1 |
The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors of formula (I). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and...
|
|
WO/2019/242719A1 |
The present invention relates to a salt form of (R)-N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluo
ro-4-(6-fluoro-1-methyl-1,2,3,4-tetrahydrobenzo[4,5]imidazo[
1,2-a]pyridin-8-yl)pyrimidin-2-amine (compound I) as shown in struc...
|
|
WO/2019/238088A1 |
A salt form and a crystal form of a pyridopyridone derivative and a preparation method therefor. Specifically, disclosed are a hydrochloride salt of the compound of formula (I) and a crystal form of the hydrochloride salt thereof, and us...
|
|
WO/2019/233883A1 |
The present invention relates to novel compounds of formula (I) that can be employed in the treatment, alleviation or prevention of a group of disorders and abnormalities associated with Tau (Tubulin associated unit) protein aggregates i...
|
|
WO/2019/233372A1 |
Disclosed is a substituted pyrazolyl pyrazole sulfonamide compound or a pesticidally acceptable salt thereof, a composition, and a use thereof. The compound has a structure represented by formula (I). The definition of each group in the ...
|
|
WO/2019/230905A1 |
The present invention addresses the problem of providing a halogenated biotin-modified dimer which allows imaging diagnosis or treatment by labeling, with a halogen element, a biotin-modified dimer which has a high affinity for a strepta...
|
|
WO/2019/228940A1 |
The present invention relates to novel compounds of formula (I), wherein R1 , R2, R3, R4, R5, R6 and R7 are as described herein, and their pharmaceutically 5 acceptable salt, enantiomer or diastereomer thereof, and compositions including...
|
|
WO/2019/229765A1 |
The invention described herein relates to the compounds of Formula I for treating diseases and disorders for which inhibition or modulation of the topoisomerase I enzyme produces a physiologically beneficial response, in particular for t...
|
|
WO/2019/232223A1 |
Described are compounds of formula (I), based on an isoquinolin-1(2H)-one backbone, that function as Hsp90β selective inhibitors. Also described are pharmaceutical compositions thereof and methods of treating cancer by administering com...
|
|
WO/2019/223788A1 |
The present application relates to a compound of formula I as a toll-Like receptor 7 (TLR7) agonist or a pharmaceutically acceptable salt thereof for treating lung cancer, a pharmaceutical combination of the TLR7 agonist and a tyrosine k...
|
|
WO/2019/220155A1 |
The present invention relates to novel imidazo[1,2-b]pyrazole carboxamide and carbothioamide derivatives of general formula (V), and the advantageous derivatives and pharmaceutically acceptable salts thereof, the synthesis thereof, and m...
|
|
WO/2019/218955A1 |
Provided is a series of compounds used as protease inhibitory receptor 4 (PAR4) inhibitors for treating platelet aggregation and medical use thereof, relating to the technical field of chemical medicines.
|
|
WO/2019/222173A1 |
The present invention is directed to fused tetrazoles of formula (IA) which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
|
|
WO/2019/222677A1 |
This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases r...
|
|
WO/2019/218876A1 |
A fluorescent probe and a preparation method and use thereof. The fluorescent probe responds sensitively to viscosity, is specific, and can be used for specific fluorescent labeling of a protein. The fluorescent probe can also be used fo...
|
|
WO/2019/222069A1 |
The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, and R4 are as defined as set forth in the specification. The present disclosure also ...
|
|
WO/2019/218957A1 |
A compound as a protease activated receptor 4 (PAR4) inhibitor for treating platelet aggregation and a medical application thereof, belonging to the technical field of chemical drugs.
|
|
WO/2019/218956A1 |
The invention falls within the technical field of chemical medicine. Specifically provided are a series of compounds acting as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation, and a medical use thereof.
|
|
WO/2019/216294A1 |
The purpose of the present invention is to provide compounds having an M3 PAM action. Examples of the present invention include azabenzimidazole compounds represented, for example, by formula [I], and pharmacologically acceptable salts t...
|
|
WO/2019/214656A1 |
A fluorine-containing isoxazole compound, a preparation method therefor, and a pharmaceutical composition and use thereof. Specifically, disclosed is a compound represented by general formula I or enantiomers or diastereoisomers thereof,...
|
|
WO/2019/213119A1 |
Compounds that may inhibit Oplophorus-derived luciferases are disclosed as well as compositions and kits comprising the compounds and methods of using the compounds.
|
|
WO/2019/212991A1 |
The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
|
|
WO/2019/210835A1 |
A diaryl macrocyclic compound as a protein kinase modulator. Specifically, the present invention relates to a compound in formula I or a pharmaceutically acceptable salt thereof, a preparation method therefor and a pharmaceutical composi...
|
|
WO/2019/212990A1 |
The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
|
|
WO/2019/175607A9 |
The complex chemistry underlying the extensive transformations involved in terpene indole alkaloid synthesis makes identification of the biosynthetic genes challenging. The present invention relates to methods for producing a terpene ind...
|
|
WO/2019/209896A1 |
The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as ...
|
|
WO/2019/208509A1 |
The present invention provides a compound which has an effect of inhibiting amyloid β production, especially an effect of inhibiting selective BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by pro...
|
|
WO/2019/204446A1 |
Described herein are polymorphs comprising 2',6-difluoro-5'-[3-(1-hydroxy-1-methylethyl)-imidazo[1,2-b]
[1,2,4]triazin-7-yl]biphenyl-2-carbonitrile (TPA023B) or salts thereof. In one aspect, disclosed herein is a crystalline polymorphic ...
|
|
WO/2019/200120A1 |
The invention provides dihydroisoquinoline-2(1H)-carboxamide and related compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as cancer, and in inhibiting HPK1 activity.
|
|
WO/2019/197602A1 |
A compound with the formula I: (I) and salts and solvates thereof, wherein: R" is a group of formula II: (II) where each of n and m are independently selected from 1, 2 and 3.
|
|
WO/2019/197549A1 |
The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[l,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for th...
|
|
WO/2019/199908A1 |
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compos...
|
|
WO/2019/196948A1 |
Disclosed are a compound using an aryl ketone as a core as represented by general formula (1), a preparation method therefor and an application thereof on an OLED. A parent nucleus of the organic compound is an aryl ketone, the parent nu...
|
|
WO/2019/195104A1 |
The present disclosure relates to compounds of Formula (I) or (II), as compounds capable of emitting delayed fluorescence, and uses of the compounds in organic light-emitting diodes.
|
|
WO/2019/189867A1 |
The technical problem of the present invention is to provide a bis-iminobiotin compound which has a structure that enables the easy bonding of a bis-iminobiotin moiety to a drug or a fluorescent compound and is useful for the delivery of...
|
|
WO/2019/184955A1 |
Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2019/191454A1 |
The present disclosure relates to compounds of Formula (I), (II), or (III) as compounds capable of emitting delayed fluorescence, and uses of the compounds in organic light-emitting diodes.
|
|
WO/2019/186358A1 |
The invention relates to compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutical co...
|
|
WO/2019/189732A1 |
The present invention pertains to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, said compound inhibiting the binding of an MLL fusion protein, in which a typical fusion partner gene such as AF4 or A...
|
|
WO/2019/186343A1 |
The invention relates to compounds of the formula (I) (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification; to intermediates in the preparation of the compounds, to pharmaceutica...
|
|
WO/2019/189778A1 |
A compound with anticancer activity or a pharmaceutically permissible salt thereof is provided. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof is used. (In the formula, L1 andL2 are the same or differ...
|
|
WO/2019/180683A1 |
The present disclosure provides novel compounds of Formula (I) below. Compounds of the disclosure act as STING modulators/agonists. The present disclosure further relates to methods of synthesis of compounds of Formula (I) and methods of...
|
|
WO/2019/181645A1 |
Provided is a compound having an acceptor unit, and a donor unit that has a specific structure. Another purpose of the present invention is to provide a precursor to said compound. Another purpose of the present invention is to provide a...
|
|
WO/2019/183364A1 |
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further ...
|
|
WO/2019/182960A1 |
Compounds of Formula (1) as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases asso...
|
|
WO/2019/175046A1 |
The present invention relates to novel condensed bicyclic heterocyclic derivatives of formula (I), wherein B1, B2, B3, B4, R1, R4, R5, R6 and n have the above-mentioned meanings, to agrochemical formulations containing the compounds acco...
|
|
WO/2019/174634A1 |
A pharmaceutical intermediate compound 3, a preparation method therefor, and use of the compound 3 in the preparation of other compounds.
|
|
WO/2019/174598A1 |
Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2019/178129A1 |
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
|
